Novavax (NVAX) EBITDA Margin Growth (5y) (2015 - 2026)
Novavax (NVAX) EBITDA Margin Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,559.00 |
| Dec 31, 2025 | 7,506.00 |
| Sep 30, 2025 | -12,919.00 |
| Jun 30, 2025 | 10,567.00 |
| Mar 31, 2025 | 75,536.00 |
| Dec 31, 2024 | 17,717.00 |
| Sep 30, 2024 | 43,923.00 |
| Jun 30, 2024 | 113,097.00 |
| Mar 31, 2024 | 85,581.00 |
| Dec 31, 2023 | 69,612.00 |
| Sep 30, 2023 | 47,451.00 |
| Jun 30, 2023 | 40,286.00 |
| Mar 31, 2023 | 6,440.00 |
| Dec 31, 2022 | 39,069.00 |
| Sep 30, 2022 | 48,110.00 |
| Jun 30, 2022 | 35,627.00 |
| Mar 31, 2022 | 74,850.00 |
| Sep 30, 2021 | 198,888.00 |
| Jun 30, 2021 | 144,514.00 |
| Mar 31, 2021 | 173,766.00 |